Seems like a pretty terrible business decision if they decided to not monetize shareholder value now in Q3 with a partnership in Europe or hybrid approach like they have been saying...makes no sense to not get a life saving drug to millions of Europeans asap than for them wait to hear on the US appeal first. That would create an outrage among shareholders...